Table 1. Patients, diseases, and transplant characteristics (n=282).
| Characteristic | Value | ||
|---|---|---|---|
| Median patient age, years (range) | 54 (5-74) | ||
| Recipient gender (M/F), # pts (%) | 182 (65) / 100 (35) | ||
| Median donor age, years (range) | 45 (19-78) | ||
| Donor gender (M/F), # pts (%) | 147 (52) / 135 (48) | ||
| Diagnosis, # pts (%) | |||
| Acute myeloid leukemia | 63 (22.3) | ||
| Acute lymphoblastic leukemia | 8 (2.8) | ||
| Chronic myeloid leukemia | 15 (5.3) | ||
| Chronic lymphocytic leukemia | 33 (11.7) | ||
| Myelodysplastic syndrome | 31 (11.0) | ||
| Multiple myeloma | 44 (15.6) | ||
| Non-Hodgkin lymphoma | 52 (18.4) | ||
| Hodgkin disease | 25 (8.9) | ||
| Waldenström macroglobulinemia | 3 (1.0) | ||
| Renal cell carcinoma | 7 (2.5) | ||
| Cervical cancer | 1 (0.4) | ||
| Disease risk, # pts (%) | |||
| Indolent* | 123 (44) | ||
| Aggressive† | 159 (56) | ||
| Tandem autologous/allogeneic HCT, # pts (%) | 41 (14.5%) | ||
| Donor, # pts (%) | |||
| Related | |||
| HLA-identical | 152 (53.9) | ||
| 1 HLA-antigen mismatched | 1 (0.4) | ||
| Unrelated | |||
| 10/10 HLA allele-matched | 95 (33.7) | ||
| 1 HLA-allele mismatched | 16 (5.7) | ||
| 1 HLA-antigen mismatched | 13 (4.6) | ||
| 1 HLA-antigen + 1 HLA allele mismatched | 5 (1.8) | ||
| Numbers of inhibitory genes on donor NK cell KIR, # pts (%) | |||
| Unknown | 30 (11) | ||
| 2 | 6 (2) | ||
| 3 | 91 (32) | ||
| 4 | 104 (37) | ||
| 5 | 51 (18) | ||
| Number of activating genes on donor NK cell KIR, # pts (%) | |||
| Unknown | 53 (18.8) | ||
| 1 | 77 (27.3) | ||
| 2 | 46 (16.3) | ||
| 3 | 21 (7.4) | ||
| 4 | 37 (13.1) | ||
| 5 | 33 (11.7) | ||
| 6 | 15 (5.3) | ||
| Hematopoietic stem cell source, # pts (%) | |||
| G-PBMC | 271 (96) | ||
| Bone marrow | 11 (4) | ||
| Conditioning regimen, # pts (%) | |||
| 2 Gy TBI | 54 (19) | ||
| 2 Gy TBI + fludarabine | 228 (81) | ||
| Cell dose, median (range) (× 106/kg recipient) | |||
| CD34+ cells | 7.8 (0.8-42.6) | ||
| T cells | 312 (16-934) | ||
| Sustained engraftment / graft rejection, # pts (%) | 264 (94) / 18 (6) | ||
| Acute GVHD, # pts (%) | |||
| Grade | 0 /1 | 113 (40.1) | |
| 2 | 127 (45.0) | ||
| 3 | 31 (11.0) | ||
| 4 | 11 (3.9) | ||
| Chronic GVHD, # pts (%) | |||
| No | 135 (48) | ||
| Yes | 147 (52) | ||
| 3-year overall survival (%) | 50 | ||
| 3-year progression-free survival (%) | 37 | ||
*
Defined as acute myeloid leukemia in first complete remission, acute lymphoblastic leukemia in first complete remission, myelodysplastic syndrome-refractory anemia, chronic myeloid leukemia in first chronic phase, chronic lymphoblastic leukemia, low-grade non Hodgkin lymphoma, multiple myeloma in partial or complete remission, and Waldenstrom macroglobulinemia.
†
All other diagnoses.
M, male; F, female; R, recipient; D, donor; G-PBMC, G-CSF-mobilized peripheral blood mononuclear cells; TBI, total body irradiation; GVHD, graft-versus-host disease; KIR, killer cell immunoglobulin-like receptor.